Annual revenue of Sinovac Biotech Ltd. 2016-2023

In 2023, Sinovac Biotech Ltd., one of China’s major vaccine producers, recorded an annual revenue of 448.27 billion U.S. dollars. In comparison to 2020, the company's annual revenue increased almost 37 times in 2021, reaching almost 20 billion U.S. dollars. CoronaVacSinovac's substantial growth is largely driven by the strong demand for CoronaVac, its COVID-19 vaccine. By the end of January 2022, almost 2.5 billion doses of CoronaVac were manufactured in production sites within China and abroad, ranking Sinovac as one of the most prominent COVID-19 vaccine suppliers globally.  The international marketUnlike CanSino Biologics Inc., which heavily relies on international sales, Sinovac sold most of its products within China’s borders. However, a considerable share of Sinovac’s COVID-19 vaccine doses was also exported through sales and donations, primarily to middle-income economies. The inactivated vaccine is adopted by dozens of countries and recognized by the World Health Organization, despite having a lower efficacy rate against COVID-19 than mRNA vaccines such as Comirnaty and Moderna’s Spikevax.

于2023年，中国主要疫苗生产商之一的科兴生物技术有限公司，实现了4482.7亿美元的年度收入。相较于2020年，该公司在2021年的年度收入增长了近37倍，达到近200亿美元。科兴生物的显著增长主要得益于其COVID-19疫苗CoronaVac的强劲市场需求。截至2022年1月底，科兴生物在中国及海外生产基地共生产了近25亿剂CoronaVac疫苗，使其成为全球最杰出的COVID-19疫苗供应商之一。与主要依赖国际销售的康希诺生物有限公司不同，科兴生物的大部分产品销售在中国境内。然而，科兴生物的相当一部分COVID-19疫苗剂量也通过销售和捐赠出口，主要流向中等收入经济体。尽管在针对COVID-19的有效率方面低于Comirnaty和Moderna的Spikevax等mRNA疫苗，但该灭活疫苗仍被数十个国家采用，并获得世界卫生组织的认可。